InvestorsHub Logo
Followers 834
Posts 119884
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 972

Tuesday, 06/22/2021 3:23:40 PM

Tuesday, June 22, 2021 3:23:40 PM

Post# of 1162
BMY settles US Revlimid-patent case with another challenger—Sun Pharma—on similar terms to prior settlements—(e.g. #msg-158350306):

https://www.fiercepharma.com/manufacturing/bristol-myers-settles-sun-pharma-for-limited-revlimid-generic-launch-2022

The basic framework of these settlements is: a) the generic-drug companies who settled can launch limited quantities their Revilimid generics in the US market in 2022 (Mar 2022 for Natco [the first company to settle with BMY]; and somewhat later in 2022 for RDY, Cipla, and Sun Pharma); and 2) the generic-drug companies who settled can launch unlimited quantities of their Revlimid generics starting on 1/31/26.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News